Okay, great. Thank you, everybody, for joining us today. For those of you who do not know me, I am Rudy Kessinger. I cover Security and Infrastructure Software here at D.A. Davidson, and we have pretty much the whole management team from Cellebrite joining us today. We have CEO, Shiv Ramji, CFO, David Barter, CTO, Chris Wade, and VP of IR and Treasury, Andy Kramer. Appreciate all of you for joining. Andy, I will kick it over to you real quick, just for the safe harbor, and then we will jump into things here. Yeah, absolutely. Thank you very much, and good afternoon, good evening, good morning to those of you who are joining. I would like to remind everybody that today's discussion will contain some forward-looking statements that include, but are not limited to, the company's business operations, product roadmaps, and financial performance. All forward-looking statements are subject to risks and uncertainties and other factors that could cause matters expressed or implied by those forward-looking statements not to occur. Actual results could also differ materially from historical results and/or from forecasts. Some of those forward-looking statements are discussed under the heading Risk Factors and elsewhere in the company's annual report on Form 20-F, filed with the SEC on March 3rd, 2026. The company does not undertake to update any forward-looking statements to reflect future events or circumstances. With that said, I will turn the call and the event back over to you, Rudy. Okay, great. Shiv, I want to start with you. I think a lot of investors really appreciated your message of accountability and the need to execute better on the earnings call, and that is kind of where I want to start. As you have been in the CEO seat for a month now, could you share just your learnings about the business as a whole and where the greatest opportunities for improvement and execution lie going forward? Yeah. Good morning, good afternoon, good evening to everybody, and thanks for hosting us. So yeah, I spent the past month, really a lot of the time was with customers and of course our teams and leadership. As you can imagine, I have also spent a lot of time with many shareholders too. So had lots of meetings with that audience. Some of this is really just a continuation of my first 90 days. Now obviously, I am spending more time with some of the decisions that are really critical for our growth and making sure that we execute the quarter. Stepping back, there is a substantial opportunity for growth here. I still believe, and in fact my conviction is growing as I learn more about our business and our customers. I think we have a really, really big opportunity to have a platform play and becoming a trusted investigative intelligence platform. I still see the potential of this business growing significantly in the future, and also delivering durable growth. So, solid top-line ARR and continuing to deliver on free cash flows. In terms of key strengths of the business and some initial observations, I think really impressed by all of our teams. We have a deep technical bench in the company, our leadership in digital forensics, and this really comes to life when you go talk to customers. I spent some time in Europe, and meeting some customers here in the U.S., and it's pretty clear that they are reliant on our products and services and really want us to innovate more. Strong customer base, strong relationships, and that we still have a very strong balance sheet. I think our revolution is really just going to be moving from, today we're a collection of very critical and important products to becoming a trusted investigative intelligence platform. We want to continue to deliver our innovation that we started across AI and cloud. We want to make sure that we deliver on this in the next quarter, and then come back to our shareholders later this year to talk about our FY 2027 plans. Got it. That's a great intro there. From here, I kind of want to go in order from your digital forensics business, which has been your core market. It's where the majority of your business is today, and then into your workflow management, analytics, and virtualization, where you've launched new products. After that, we'll dive into durability, growth, and perhaps some other numbers-oriented questions. Firstly, Cellebrite is the market leader in digital forensics for mobile phones. Is there an update on the competitive landscape you can share there? This has historically been a multi-vendor market, especially when it comes to access and unlocks. In Cellebrite, historically, you've been stronger on Android, a bit of a leapfrog on Apple iOS. Just given the improved Android unlock capabilities, is that leading to any share gains with your customers who use both you and your largest competitor? Yeah. A few things to think about the current digital forensics market, right? When you, especially the larger agencies that we have, they are more likely to have a multitude of tools and technology. Typically, they will have other vendors in there. They kind of have to, just given the nature of the work that they're doing. But we've been a primary vendor for mobile phone extraction for well over a decade for lots of our customers. You can see that, right, in terms of this reflects those strengths across access, extraction, and decoding. Each phase of the examination is really important, and we deliver World-class capabilities in each of these domains. Our coverage spans both Android and Apple iOS. But a little bit about the space is it's a little bit of a cat-and-mouse game. There are times when maybe we have all the capabilities across all of these domains, especially unlocks and extractions. Sometimes our competitors will have. It is always shifting and changing. From a market share perspective, which is what you asked me, we haven't seen anything in our data yet that we have lost any share. Everything that we track, we are the dominant player in the market. That is where we sit and it is still a multi-vendor environment. As of today, which we announced earlier, and this is why we have Chris on the call, we moved our Cellebrite Labs team under his leadership. He has been a domain expert here for a very long time. He is spending his time and additional investments to make sure that we continue to have all of the capabilities that we need for our customers across both iOS and Android. Maybe, Chris, you can add a little bit of color around some of these capabilities. Yeah, I think going back to what you said about the testament to our world-class capabilities, Android is extremely fragmented. There are hundreds of different OEMs making phones, and we lead the way with this. We have a phenomenal Android team. Now that I am leading Labs, we are going to continue the investment and expand, adding capabilities on AI side, as well as expanding the team. We ensure that we have the dominance on the Android side and start to push heavily on the iOS side as well. Got it. Chris, I was planning to segue to you next, but Shiv, Chris, both you, I guess here, there has been a lot of investor questions around AI and potentially enhancing Apple and Android's ability to find and close off the vulnerabilities that you guys exploit to unlock those locked phones. Firstly there, any change in behavior from the Android and Apple OEMs? Secondly, Chris, with you heading Cellebrite Labs on the mobile research, can you guys talk about just how exactly you are doubling down on that research and what exact initiatives you have in place to ensure that Cellebrite is unlocking phones regardless of what the OEMs do for many years to come? Yeah, I think we've seen something similar to this AI lifecycle compression a few years ago when fuzzing became very popular. You see this initial number of bugs goes through the roof, and eventually plateaus. But we noticed this compression, and we're using AI on our side. We've just made a heavy investment in hardware and software on the AI side to combat Apple and Google's use of AI. The next six months are going to be very interesting as we see the models evolve, the frontier models just getting better and better. But what we've seen in the last few months is the rate at which new bugs are introduced hasn't gone down. AI hasn't stopped the fundamental problem of bugs in software. So we're seeing the vulnerabilities be patched faster, but we're not actually seeing a reduction in the number of vulnerabilities. Got it. Super helpful. Just coming back to the digital forensics more holistically, how much new logo and expansion opportunity remains in the digital forensics business? Or at this point, is it more about providing new digital forensics tools and technologies outside of the lab? It is still the majority of your growth today. So I guess just how much runway is there in that core digital forensics business? I'll start. Quite a bit, and I'll tell you why. The more I learn about this business and go deep, and we are really deeply penetrated today in what I call the digital forensics labs. So very heavy lab focus. A few years ago, we started this journey of starting to address other personas and ICPs. So we now have Guardian for investigators. But today we do not serve prosecutors at all. So, we have a very big opportunity here to expand to prosecutors. Corrections facilities, there's another group of users there where we can provide workflow capabilities. So just in public safety alone, we both have the opportunity to provide products that improve the investigative workflow. We have products that will serve entirely net new users. Then we want to add capabilities, I think, especially with what we've done with Genesis and with AI. It gives us an opportunity to provide a cloud solution, which we have launched. We're now also working on on-prem or air gap solutions for certain agencies and in specific geographies. They are not ready to use models in the cloud, so providing a solution that respects their privacy or data rights, or sovereignty, then those are amazing opportunities for us. So I think there is quite a bit of wood to chop just in law enforcement and public safety. Then, I look at the other market segments, those are different. Federal is a really big, important focus area for us. We've been investing in, with the FedRAMP High authorization. We have lots of opportunity in defense and intelligence. We're just getting started. We actually launched a product about two to three weeks ago, which is a tactical kit for combat in the field. We have some very interesting and unique capabilities today serving the private sector customers. It's a very small business today, but I think, again, we have lots of interesting capabilities, some of which would include products from the recent Corellium acquisition we've done. I think you will see a lot more when we go into next year, a lot more around how we plan to serve some of our private sector customers also. Those are separate from our core public safety or law enforcement opportunity. Got it. Okay, shifting on some of these new products you talked about, particularly Guardian and Genesis, but also Pathfinder, maybe Corellium, too. Could you talk about the value your customers are seeing in those products, the technical differentiation, the barriers to replication, and when you expect those products to become a more meaningful driver of ARR growth? Yeah. Let's start with each separately. I think when you think of Guardian, Guardian really was our first move into starting to solve for different workflow needs. Moving away from just being a product that is used for extraction to now moving it beyond extraction into the investigative workflow to provide evidence. There, Guardian really is not displacing any other solution. It's really providing a workflow capability to what is typically a very manual process. Our customers really are moving USB drives and thumb drives around. Guardian really provides this amazing workflow, both from a storage and collaboration perspective, but then also allows our customers to use Guardian to digitize their standard operating procedures. That's Guardian, and there are several modules there that we're working on to expand that product set. When you think of Pathfinder, this is really a purpose-built on-prem solution that helps customers analyze mobile phone data for crimes and events at scale. Think when you have to process lots of phones. This has been really, really powerful. We have some really large public sector customers who have deployed these in different environments. It's a more technically complex product because it's solving some complex use cases for our customers. Genesis, which we launched earlier this year, just a few months ago on June 10th. It's a product that's built from the ground up with agentic AI at the core, and it can really analyze multiple data sources, including phone data, to really help our customers get to actions or resolving specific investigations quickly. Genesis has really surprised us in many ways because when you go to customers and we say, "Hey," and they start using the product, which we are also testing something new here, which is we are testing a product-led growth motion. So you can have a 60-day free trial period, and then customers upgrade to a paid version. It has been pretty impressive. I see lots of notes from our customers where they conclude how the product helped them find new leads, how the product helped them get to actions much faster, and then we are starting to see in some cases where customers will start small, and then as they learn how they are using the credits, they are looking to expand further on our platform. It has been really interesting to watch that because I think we have a lot to learn there, and there will be interesting data points there with regard to how they end up allocating budgets for this, and also how much AI they start using in their day-to-day workflow. So these are the three different products, and each of them are solving different use cases. In the future, you will see all of these products ultimately combined to our Genesis platform, and then you will just get different deployment models with different. You can get Genesis in the cloud, you will get Genesis on-prem, you may even get a version of Genesis on-prem with an FDE or field deployed engineer, because that is also something that we are experimenting with. So there will be a convergence here of all of these products into the core Genesis platform. Got it. Okay. I guess in terms of customer segments, defense intelligence, you already noted that earlier in this call, that was a strong grower in Q2. Just what is happening in that segment that is contributing to this type of standout performance? For D&I, we just have a lot of demand. As you can imagine, globally, the threat vectors are accelerating, and devices and digital evidence are the center of it. So, a lot of the demand there has been, we kind of address this market with our existing product set, which has been great, but we are also getting specific requirements from our customers. They want to see different form factors. They want the ability to have mobile labs in the field, including the ability to create form factors such that maybe everybody, every person who is in the military, could potentially carry a Cellebrite device on them for the purpose of extracting intelligence and acting on it quickly. Starting the second half of this year, we acquired SCG Canada for drone forensics, so that hardware product is coming to market at the end of this year in CFID v4. We launched the tactical kit about two weeks ago, which is a purpose-built kit for the military. We have new portable kits in development which we will launch next year, including some prototypes of devices that Chris is working on where they are more portable and anybody can carry those devices with them for the purpose of extracting intelligence. I think we are being very purposeful in serving this market, and are bringing very specific products to address the market needs. I do not know, Chris, if you want to add anything with regards to the new hardware models that we are working on. Yeah. So we are working on, as Shiv mentioned, field portable, battery-powered that do not require any kind of connectivity. They can run in offline or a cloud sync mode and have edge processing capabilities running SLMs on board. It is the first iteration of our next gen hardware that we are actually designing in-house at Cellebrite. It will be the first piece of hardware that has been end-to-end designed by Cellebrite and manufactured in America. We are pretty excited about it. I think you are— Sorry, on mute there. Yeah. Sorry. I want to come back to Genesis. Just double-clicking the go-to-market strategy there. It sounds like the free tier is 60 days, and then maybe convert customers just, how is that going? How do you think about evolving that strategy going forward? Then maybe jumping the gun with a question I had for David later just on gross margins. How might that impact the gross margin profile with that free tier and the token-based pricing and things like that? I will unmute. Sorry. I think early signals from Genesis are pretty encouraging. I think we had highlighted that we have more than half a dozen paying customers. Roughly at the last call, we said we are roughly at about ILS 1 million in ARR on that product. The adoption has been healthy and continued since then. The other good news is we are actually starting to see customers in all major geographies and segments who are excited about this. We still have a lot of capabilities to build out, so a pretty robust roadmap. We just did an update about two weeks ago where we released a bunch of new capabilities, including a capability called Deep Investigator. So, that has been good. Then from a trial perspective, I think we continue to see a good progression of trials and converting them into paid customers. As we end this quarter, I think we will have additional trends and insights to build on, but so far, the early signs are pretty encouraging. Dave, do you want to talk about margins? Yeah, I do. Thank you, Shiv. Really, in terms of our margin structure, you started to bring together the free tier together with paid, so let me break them back out for you. The way we actually structure it is that the free tier does run through sales and marketing in line with all of our peers. That free tier is, in part, a commitment to our customers to ultimately adopt AI, and also being a very mission-driven company, certainly all of law enforcement want to make sure that they have access to it. Part of our mission is just having a robust free tier certainly allows us to be true to our values in terms of making sure that we are doing everything possible to help our customers solve crime. That element will continue to sit in sales and marketing, and that will be a de minimis element of cost because when you have your hyperscaler contract, you can negotiate specific rates on sales and marketing versus R&D versus cost of revenue. Getting to the cost of revenue component, an AI workload is not as profitable. As you know, Rudy, y ou are a great student of our company. We tend to run at about 85% or 86% gross margins. I do not think AI in its first rev will be at that level, no different than probably how cloud started off at a little bit of a lower gross margin. But I think overall it will be very accretive to the company, and over time, I suspect that gross margin will continue to climb back up. Got it. Okay. Then maybe just one more going back to all these new products. Is there anything you can share about just penetration rates with Guardian? Obviously, Genesis is super new. You said over half a dozen, so we know it is very low penetration right there. Guardian, Pathfinder, Corellium, how early are you in the cross-sell and expansion playbook with these products today with your customers? Still early. I will tell you what are some of the blockers there. Let us start with Guardian. With Guardian, we obviously, we are not in all of the regions today, for example. So we want to expand in the regions that we are available in. So you will see increase in adoption with Guardian. We also ran into, as we had mentioned on the call, with Guardian, we had run into, for some markets, Freedom of Information Act. So, adoption kind of stalled and was delayed, but we expect that to also ramp up. Guardian is also relevant for the federal market. We did not have the FedRAMP High authorization. Now we do, so that is going to open up the federal customers for us. Then when you think of these different users, in the case of prosecutors or corrections facilities, we are still building out those modules. Once we have those, we will see greater adoption in the customer base. Genesis is early, but we have launched some new regions. We announced those a few weeks ago. We will probably launch additional regions there too, to continue to capture the market. So we expect that those numbers will continue to grow. But I would say still very low in terms of penetration. It is because we have some work to do on product and on geographies that we are serving. Got it. Okay. David, I want to pivot to you. Got a number of questions here, and really Shiv to you as well on some of these. But software stocks, for most on the call know, largely trade on durability of ARR growth and confidence in numbers. So I want to hit on both of those. Firstly, durability of ARR growth. How confident are you that the 15% at the midpoint of ARR growth guidance for this year is the floor for growth? Well, I'll say it differently, Rudy, we gave an outlook, and I think one of the key parts of our outlook was ultimately recognizing that we were seeing deal elongation. You saw the announcement this morning in terms of starting to get after deal elongation. One of the things that we communicated today was redomiciling the company. We think that ultimately has a lot of benefits commercially. That is certainly part of the roadmap almost as we go into next year of ultimately being able to capture that end market. I think we ultimately exercised a lot of prudence when we saw that deal cycles were elongating. I think as we kind of communicated, again, as you've kind of tracked, we continue to sign deals and take down the opportunity because cloud and AI represent tremendous opportunities within public safety given the threats that are impacting our communities. I'd say we're remaining bullish on that opportunity, but I think there's certainly a lot of prudence and a lot of humility that went in. Again, I think as you started the call, we took a lot of accountability for Q2 and then ultimately our outlook. Yeah. Then maybe let me just throw a follow-up in there on the redomiciling. Could you talk about twofold there? One, process-wise, what is this going to look like, timeline? Just more details on the process there. Secondly, you did call out some of those elongated deals, some of those extra loopholes you had to jump through because you were a foreign filer. How much will this redomiciling in the U.S. alleviate or ease those kind of sales cycles with large federal accounts? No, we think that over time it actually has a substantial impact as we go into FY 2027, and that's why we communicated on our timeline that a lot of these activities that we need to perform along the lines of affecting and ultimately perfecting a redomiciliation take a healthy four months minimum just to get through the first wave, and then it will take several months thereafter. I think that's why we feel confident it would happen in the first half of FY 2027. Got it. Okay. First half, got it. Okay, just going back to just where I was kicking off things on the durability growth, just what will be the drivers of stability or re-acceleration in ARR growth going forward if you had to rank order across your product portfolios or other go-to-market initiatives? Yeah. Shiv, would you like to start or do you want me to weigh in? Yeah, go ahead, then I'll add. Certainly. Yeah, I think fundamentally, Rudy, when you look at the market landscape, I'd say certainly the element around a mobile device and everything that we're doing certainly around extraction and collection, and I think what Chris hinted at in terms of the hardware as well as the software experience and how that continues to unfold, gathering larger and larger pieces of data. What was once 50 or 60 GB is now getting to half a terabyte of data that is starting to come in. So the extraction volumes are incredibly high and incredibly rich, and that ability to take that level of information and feed it into AI where it's getting enriched by nine or 10 other data artifacts seems to be a big part of the growth of the company. Unfortunately, our communities and ultimately, as Shiv highlighted, having mobility and being able to help operators in the field that are thinking about left of launch, that is a part of our mission. We take it very seriously, and as of right now, the world needs Cellebrite and the types of technologies we're introducing. Got it. Okay. I know it's likely too early or premature to talk about growth prospects for 2027 with too much detail. But you've discussed that growth products should represent, I think, upper teens as a percent of ARR mix this year. How should investors think about the framework for growth entering 2027? What needs to happen, I guess, from a platform and roadmap perspective to sustain strong growth within those new product areas? It's a great call-out. I think you're right. We're going to add about five points of favorable ARR mix in terms of the growth products, going from the lower teens to the upper teens this year. We think we feel really good about that because that gets to really your question around durability, where the growth products become a progressively larger part of the portfolio. As we go into next year, one of the things we'll be talking about is the roadmap. As we get into Q4, we'll talk about when you can see some of these products hitting the market. That will ultimately inform how we think about the growth, both in terms of the front half, but equally, we're pretty excited about the back half of FY 2027 in terms of once we have this product roadmap fully in the hands of our customers, how that starts to play out. Got it. I guess as you start to penetrate the installed base more effectively with newer products, is it your expectation that we could see improvements in gross retention rate potentially into the mid-90s over time? Well, we have certain customer segments that will hang out in the mid-90s. Our view is, particularly as we ultimately are able to sell a platform, I think you saw last quarter, we saw gross retention climb a little over a point, almost a point and a half. I think our view is the more we can actually serve a customer and have longer-term relationships, I think that actually naturally goes hand-in-hand with both a better gross retention, but certainly even a better net retention as well, just by virtue of the fact that when you have a three to five-year piece of paper with a customer, as you have new products and new innovation, it's much easier to just attach that product onto that contract. Got it. Okay. Coming back to just confidence in numbers. Again, sounds like a lot of prudence in this guide for Q3, but also the full-year. Could you quantify any of the more conservative assumptions you made around close rates, pipeline conversion, et cetera, in the Q3 and second half outlook? Yeah. I would say, Rudy, the biggest changes that we made, we really looked at our deals and the deal cycle times. Certainly, as you saw, coming out of Q2, we looked at concentration of net new ARR on some key accounts and tried to appropriately judge those where we said, "Gosh, while they're key relationships and they might be big six figure going into seven figure or already seven-figure contracts, let's maybe moderate how much net new ARR we're contemplating recognizing there's a base case and there's some upside cases." Those are probably two of the bigger judgments that went into it. Okay. What are the avenues to achieving Q3 ARR guidance? More specifically, I guess, could you give some color around the opportunities in U.S. federal, the federal segment in particular in Q3, just given that's the fiscal year end, U.S. fed? Yeah. I think there are a couple of moving parts to the federal business. It's certainly how are the agencies splitting their money between actually, and this is something new for us, between September and December. So we're looking at how they're approaching spending the money for both this year as well as going into the next fiscal year, which some of them are spreading their appropriations across the two years. So that's one dimension. The other dimension is that we're also aware that through the one big, beautiful bill, there are grants that are pushing down to the states, and some of those grants will ultimately have effect in September, but some of those will have an effect in December as well. So I'd say we're carefully monitoring with our customers that cycle time around deals, and specifically when certain monies get spent in certain quarters. I think there's a higher level of customer intimacy, just realizing that deal cycles were elongating. Okay. How are you refining go-to-market pipeline hygiene, sales comp plans, forecasting, et cetera, to limit the risk that we have a repeat of Q2 where we miss the expectation on ARR and have to lower the rest of the year? Well, I think we're going back to the basics. I mean, the great thing about being in a vertical software company is you can count your customers. I think as we think about 2027, I think we're being very thoughtful. When you have a population of 7,000 customers and you can cohort them specifically exactly the way you were thinking about it, of D&I versus where we are with LEAs and certainly the enterprise, it allows us to naturally cohort our customers and think about our customer base expansion plan and ultimately how we intend to renew and expand our agreements. So we'll spend extra time this year really going through that renewal process of how we think about the relationships, then mapping it closely to the product roadmap that the R&D team has been fleshing out. Okay. Just your assumptions around adjusted EBITDA free cash flow conversion rates, I guess this year you've made the comment expect 30%+ free cash flow, but just any color on your assumptions around that conversion versus adjusted EBITDA this year? I think, again, you're a great student of the business. I think the back half of our business is always seasonally stronger in terms of that conversion, and particularly how the cash flow materializes. I think you saw that in the outlook that we provided in terms of comparing H2 profitability versus H1. Even last year, I think we had + 80 million or so of free cash flowing in Q4. Some of this is just linked to the way our contracts are structured in terms of when payments ultimately come to us. But I think we're still feeling good about the fundamentals of the business. Particularly for a year where we've taken on about three points of FX pressure. That does move the needle in terms of how we thought about the overall expansion rates and then how we're thinking about the business for 2027. Yeah. Okay. Just for 2027, I guess just your optimism around further progression in terms of profitability and free cash flow margins, I guess. Obviously, FX is a wild card. It could swing either way, but that aside, I guess your expectations there. Well, I guess for FX, the shekel isn't quite at its all-time strength, but it's pretty close. I think the amount of compression that we've seen in profitability, just given the strength of the shekel, it's hard to imagine it moving as much. Well, it always could, but it moving as much next year as it did this year is not, I'd say, a likely scenario. But we've absorbed that FX pressure, I guess, really going back to key drivers. Headcount across the business has been very flat as we continue to focus on AI. I think that's going to be one of the elements that even if FX were to come up, I think the ability to continue driving automation using deterministic workflow agents or how we develop software or how we transact and go to market, I think all parts of the business will benefit from the investments we're making in AI. Okay. That, for me, is probably a big structural driver where in any given year, you'd be normally growing headcount in line with revenue, and that's just no longer the case. So that piece will ultimately contribute substantial leverage. Super helpful. Okay. Shiv, maybe back to you here, and maybe David certainly chime in as well, but just the update on SUNCORPORATION. The ownership is obviously an overhang in the stock. I think it was about a year ago today, I think it was you guys' Q3 call, Tom had made the comment, feel incrementally better about something happening in the next year or two. When should we expect to see some kind of structured reduction in their ownership stake? Yeah. I can go. Firstly, they've been a long-time supporter and shareholder of Cellebrite. We obviously appreciate that, but we've started to see change in their corporate governance. That's an area to keep an eye on. While it's taking time, I think there are opportunities over the next two to three-year horizon where there will be a structured and organized way for them to reduce their stake. So that's still being worked through, and we're fairly optimistic that that will be the case. It might just take a little bit longer, but that work stream is in progress. Is there any potential for this re-domiciling in the U.S. to help accelerate that or have anything take place around that? I don't think this is particular to accelerate that, but these are steps that certainly help towards that. It's one of the many steps that we are orchestrating. But in of itself is not the reason, I think. I think the reasons for re-domicile is we want to continue to grow our U.S. business, and so it makes sense to be domiciled in the U.S.. Yeah. Okay. We're coming up on time here. One thing I've heard this since that a number of times throughout this call is just the platform. I know it sounds like we're probably going to hear more about this in Q4, but I guess to date, for me, and you've talked about this, Andy, David, during myself and you two, products are kind of separate products, but they are each their own standalone product. I guess as part of this platform vision, do you envision having some kind of more cohesive product and packaging motion going forward where your customers can come in and they buy a package and they get these several products to ease the friction of the product by product selling? Yes, absolutely. We'll unpack this and talk about specifics when we go into FY 2027. Our North Star is to really become the trusted platform for investigations and intelligence-led operations. We want to do that across digital data from across devices and sources. Today, obviously, it's mobile and drones, but there are other data sources. Expect us to procure additional data sources. Then providing this platform that turns all of this into defensible evidence and mission-ready intelligence and informed action, right? You're going to see the strategic shift from examiner-centric tools to this trusted investigation intelligence across public safety, federal D&I, and enterprise. The way our customers will experience the platform will be in the form of different deployment models. I talked about the cloud version. You will have an on-prem air-gapped version. You will have a field version. Think of a mobile lab or a device that you can carry with you that it's portable. The product will be experienced in different deployment models, but that's our platform story, and we'll be talking a lot more about it. Finally tied to that is there's an opportunity here also to package our products better than we have. Thinking about platform licenses and all of the usage-based models that we have now, we could package those differently. Lots of work to do there, and you'll start seeing some of that next year. Okay. Well, looking forward to hearing more about that as the year progresses. We're up on time there, so we'll go ahead and wrap it up there. Shiv, David, Chris, Andy, appreciate all of you making the time for this today. It was a pleasure to have you guys, and have a great rest of your day and week. Rudy, thank you so much for having me. Thanks for hosting us. Thank you, everyone. Take care. Bye. Thanks. Bye-bye.